Drugs / EMZADIRIB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03997968 | Oct 2019 → Nov 2024 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, head and neck squamous cell carcinoma +7 | Cyteir Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMZADIRIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314629 ↗ |
| Known as | CYT-0851 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03997968 ↗ |
| Modality | Small molecule | — CHEMBL5314629 ↗ |
| Route | Oral | “administered orally” NCT03997968 ↗ |